Impact of BRCA2 pathogenic variants on outcomes to first-line CDK4/6 inhibitors plus endocrine therapy in HR-positive/HER2-negative metastatic breast cancer.
来源：PubMed发布日期：2026-07-22作者：Cruellas M, Rodriguez-Hernandez A, Carità L, Seguí E, Cejuela M0 次点击